申请人:Myriad Pharmaceticals, Inc.
公开号:US07678823B2
公开(公告)日:2010-03-16
The invention provides novel compounds useful for the treatment of neurodegenerative disorders including Alzheimer's disease and dementia. The compounds have a substituents chosen from -L-C(═O)OH, -L-CH═CHC(═O)OH, -L-C(═O)NH2, -L-C(═O)NH(C1-3 alkyl), -L-C(═O)N(C1-3 alkyl)2, -L-S(═O)2(C1-3alkyl), -L-S(═O)2NH2, -L-S(═O)2N(C1-3 alkyl)2, -L-S(═O)2NH(C1-3 alkyl), -L-C(═O)NHOH, -L-C(═O)CH2NH2, -L-C(═O)CH2OH, -L-C(═O)CH2SH, -L-C(═O)NHCN, -L-NHC(═O)ORo, -L-C(═O)NHRo, -L-NH(C═O)NHRo, -L-C(═O)N(Ro)2, -L-NH(C═O)N(Ro)2, -L-sulfo, -L-(2,6 difluorophenol), -L-phosphono, and -L-tetrazolyl, where L is a linker.
本发明提供了一些新型化合物,用于治疗神经退行性疾病,包括阿尔茨海默病和痴呆症。这些化合物具有取代基,选自-L-C(═O)OH,-L-CH═CHC(═O)OH,-L-C(═O)NH2,-L-C(═O)NH(C1-3烷基),-L-C(═O)N(C1-3烷基)2,-L-S(═O)2(C1-3烷基),-L-S(═O)2NH2,-L-S(═O)2N(C1-3烷基)2,-L-S(═O)2NH(C1-3烷基),-L-C(═O)NHOH,-L-C(═O)CH2NH2,-L-C(═O)CH2OH,-L-C(═O)CH2SH,-L-C(═O)NHCN,-L-NHC(═O)ORo,-L-C(═O)NHRo,-L-NH(C═O)NHRo,-L-C(═O)N(Ro)2,-L-NH(C═O)N(Ro)2,-L-磺酸基,-L-(2,6-二氟苯酚),-L-磷酸基和-L-四唑基,其中L是一个连接基。